Neumora Therapeutics, Inc.
NMRA
$1.84
-$0.13-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.91% | 11.50% | 19.85% | 33.72% | 37.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.36% | -4.01% | 14.59% | 31.19% | 40.00% |
| Operating Income | 10.36% | 4.01% | -14.59% | -31.19% | -40.00% |
| Income Before Tax | 2.80% | 19.47% | 7.99% | -1.59% | -3.37% |
| Income Tax Expenses | -26.97% | -70.85% | -53.44% | 5.60% | -33.58% |
| Earnings from Continuing Operations | 2.81% | 19.54% | 8.06% | -1.59% | -3.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.81% | 19.54% | 8.06% | -1.59% | -3.33% |
| EBIT | 10.36% | 4.01% | -14.59% | -31.19% | -40.00% |
| EBITDA | 10.23% | 3.90% | -14.71% | -31.31% | -40.16% |
| EPS Basic | 5.14% | 21.97% | 38.70% | 53.55% | 64.79% |
| Normalized Basic EPS | 7.15% | 1.56% | 26.68% | 47.20% | 61.05% |
| EPS Diluted | 5.14% | 21.97% | 38.70% | 53.55% | 64.79% |
| Normalized Diluted EPS | 7.15% | 1.56% | 26.68% | 47.20% | 61.05% |
| Average Basic Shares Outstanding | 2.51% | 2.64% | 24.64% | 65.38% | 146.21% |
| Average Diluted Shares Outstanding | 2.51% | 2.64% | 24.64% | 65.38% | 146.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |